Liminatus Pharma, Inc.
LIMN
$14.43
$1.6312.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | 03/31/2024 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -- | 255.32% | -- | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | 50.00% | -- | -- | ||
| Total Operating Expenses | 50.00% | -78.08% | -99.99% | ||
| Operating Income | -50.00% | 78.08% | 99.99% | ||
| Income Before Tax | -50.00% | 70.30% | 99.99% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -50.00% | 70.30% | 99.99% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -50.00% | 70.30% | 99.99% | ||
| EBIT | -50.00% | 78.08% | 99.99% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | -- | 71.01% | 100.00% | ||
| Normalized Basic EPS | -- | 69.77% | 100.00% | ||
| EPS Diluted | -- | 71.01% | 100.00% | ||
| Normalized Diluted EPS | -- | 69.77% | 100.00% | ||
| Average Basic Shares Outstanding | -76.82% | -0.10% | 54.23% | ||
| Average Diluted Shares Outstanding | -76.82% | -0.10% | 54.23% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||